Search Results - Vickery, Donna, MD

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study

    Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study by Choueiri, Toni K, MD, McDermott, David F, MD, Merchan, Jaime, MD, Bauer, Todd M, MD, Figlin, Robert, MD, Heath, Elisabeth I, MD, Michaelson, M Dror, MD, Arrowsmith, Edward, MD, D'Souza, Anishka, MD, Zhao, Song, MD PhD, Roy, Ananya, PhD, Perini, Rodolfo, MD, Vickery, Donna, MD, Tykodi, Scott S, MD PhD

    Published in The lancet oncology
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study

    Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study by Choueiri, Toni K, MD, Merchan, Jaime R, MD, Figlin, Robert, MD, McDermott, David F, MD, Arrowsmith, Edward, MD, Michaelson, M Dror, MD, Tykodi, Scott S, MD, Heath, Elisabeth I, MD, Spigel, David R, MD, D’Souza, Anishka, MD, Kassalow, Laurent, MS, Perini, Rodolfo F, MD, Vickery, Donna, MD, Bauer, Todd M, MD

    Published in The lancet oncology
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:

Search Tools: